Anuh Pharma Limited — PPTs, 22-08-2025: Investor Presentation

Anuh Pharma's Q1 FY26 results show robust operating revenue growth of 35% YoY to ₹186.48 Cr. Despite this, PAT saw a 12.7% decline to ₹8.30 Cr, with EPS at ₹1.66, primarily due to input cost pressures. EBITDA margin stood at 7.34%. Exports, contributing ₹88 Cr, were a key driver, with Europe (35%) and Africa (31%) leading the way.

The company is focused on expanding its global footprint with new customers and strengthening its API portfolio, especially for higher-margin products in regulated markets. Operational excellence for cost efficiency and developing complex lifestyle drugs are strategic priorities. Capacity was recently boosted to 2400 MTPA, and new products like Ticagrelor and Linagliptin are under development.

Management is confident in restoring margins through process efficiency and high-margin product sales, anticipating a steady 15-16% annual growth.